Found: 28
Select item for more details and to access through your institution.
Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.
- Published in:
- Cell Death & Disease, 2020, v. 11, n. 5, p. 1, doi. 10.1038/s41419-020-2505-1
- By:
- Publication type:
- Article
Generation and characterization of novel anti-DR4 and anti-DR5 antibodies developed by genetic immunization.
- Published in:
- Cell Death & Disease, 2019, v. 10, n. 2, p. 1, doi. 10.1038/s41419-019-1343-5
- By:
- Publication type:
- Article
Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells.
- Published in:
- International Journal of Molecular Sciences, 2018, v. 19, n. 1, p. 40, doi. 10.3390/ijms19010040
- By:
- Publication type:
- Article
The peripheral CD138<sup>+</sup> population but not the CD138<sup>−</sup> population contains myeloma clonogenic cells in plasma cell leukaemia patients.
- Published in:
- British Journal of Haematology, 2012, v. 156, n. 5, p. 679, doi. 10.1111/j.1365-2141.2011.08904.x
- By:
- Publication type:
- Article
Tumour-associated antigens in multiple myeloma.
- Published in:
- British Journal of Haematology, 2003, v. 120, n. 1, p. 3, doi. 10.1046/j.1365-2141.2003.03760.x
- By:
- Publication type:
- Article
BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1196005
- By:
- Publication type:
- Article
The origin of the plasma-cell heterogeneity.
- Published in:
- 2015
- By:
- Publication type:
- Editorial
Ectopic secretion of osteocalcin, the major non-collagenous bone protein, by the myeloma cell line NCI-H929.
- Published in:
- Journal of Bone & Mineral Research, 1996, v. 11, n. 4, p. 466, doi. 10.1002/jbmr.5650110407
- By:
- Publication type:
- Article
The selectivity of Marinopyrrole A to induce apoptosis in MCL1<sup>high</sup> BCL2<sup>low</sup> expressing myeloma cells is related to its ability to impair protein translation.
- Published in:
- British Journal of Haematology, 2018, v. 180, n. 1, p. 157, doi. 10.1111/bjh.14293
- By:
- Publication type:
- Article
BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma.
- Published in:
- British Journal of Haematology, 2017, v. 179, n. 4, p. 684, doi. 10.1111/bjh.14251
- By:
- Publication type:
- Article
Cereblon expression in multiple myeloma: not ready for prime time.
- Published in:
- British Journal of Haematology, 2013, v. 163, n. 2, p. 282, doi. 10.1111/bjh.12478
- By:
- Publication type:
- Article
A cellular model for myeloma cell growth and maturation based on an intraclonal CD45 hierarchy.
- Published in:
- Immunological Reviews, 2003, v. 194, n. 1, p. 105, doi. 10.1034/j.1600-065X.2003.00039.x
- By:
- Publication type:
- Article
Osteoclasts support the survival of human plasma cells in vitro.
- Published in:
- International Immunology, 2008, v. 20, n. 6, p. 775, doi. 10.1093/intimm/dxn035
- By:
- Publication type:
- Article
Allogeneic T lymphocytes as a source of peptide-dependent T cells specific for myeloma cells.
- Published in:
- International Immunology, 2005, v. 17, n. 9, p. 1193, doi. 10.1093/intimm/dxh296
- By:
- Publication type:
- Article
A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines.
- Published in:
- Cytometry. Part A, 2015, v. 87, n. 4, p. 285, doi. 10.1002/cyto.a.22643
- By:
- Publication type:
- Article
Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.
- Published in:
- Journal of Hematology & Oncology, 2018, v. 11, n. 1, p. N.PAG, doi. 10.1186/s13045-018-0679-0
- By:
- Publication type:
- Article
Targeting Oxidative Stress With Auranofin or Prima-1<sup>Met</sup> to Circumvent p53 or Bax/Bak Deficiency in Myeloma Cells.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00128
- By:
- Publication type:
- Article
RITA (Reactivating p53 and Inducing Tumor abnormal Apoptosis) is efficient against TP53<sup>abnormal</sup> myeloma cells independently of the p53 pathway.
- Published in:
- BMC Cancer, 2014, v. 14, n. 1, p. 1, doi. 10.1186/1471-2407-14-437
- By:
- Publication type:
- Article
RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53<sup>abnormal</sup> myeloma cells independently of the p53 pathway.
- Published in:
- BMC Cancer, 2014, v. 14, p. 1, doi. 10.1186/1471-2407-14-437
- By:
- Publication type:
- Article
RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway.
- Published in:
- 2014
- By:
- Publication type:
- journal article
The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells.
- Published in:
- European Journal of Immunology, 2000, v. 30, n. 3, p. 803, doi. 10.1002/1521-4141(200003)30:3<803::AID-IMMU803>3.0.CO;2-P
- By:
- Publication type:
- Article
Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.
- Published in:
- Hematological Oncology, 2020, v. 38, n. 4, p. 446, doi. 10.1002/hon.2750
- By:
- Publication type:
- Article
CD40 and CD95 induce programmed cell death in the human myeloma cell line XG2.
- Published in:
- British Journal of Haematology, 1997, v. 97, n. 3, p. 652, doi. 10.1046/j.1365-2141.1997.1032919.x
- By:
- Publication type:
- Article
The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis.
- Published in:
- Journal of Hematology & Oncology, 2015, v. 8, n. 1, p. 1, doi. 10.1186/s13045-015-0135-3
- By:
- Publication type:
- Article
Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis.
- Published in:
- Journal of Hematology & Oncology, 2015, v. 8, n. 1, p. 40, doi. 10.1186/s13045-015-0135-3
- By:
- Publication type:
- Article
Mcl-1<sup>128–350</sup> fragment induces apoptosis through direct interaction with Bax
- Published in:
- FEBS Letters, 2010, v. 584, n. 3, p. 487, doi. 10.1016/j.febslet.2009.11.094
- By:
- Publication type:
- Article
The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma.
- Published in:
- BMC Cancer, 2016, v. 16, p. 1, doi. 10.1186/s12885-016-2844-6
- By:
- Publication type:
- Article